Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
5.47
+0.07 (1.30%)
Jan 31, 2025, 4:00 PM EST - Market closed
Immatics Employees
As of December 31, 2023, Immatics had 535 total employees, including 432 full-time and 103 part-time employees. The number of employees increased by 93 or 21.04% compared to the previous year.
Employees
535
Change (1Y)
93
Growth (1Y)
21.04%
Revenue / Employee
$240,793
Profits / Employee
-$116,313
Market Cap
652.88M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 535 | 93 | 21.04% |
Dec 31, 2022 | 442 | 61 | 16.01% |
Dec 31, 2021 | 381 | 98 | 34.63% |
Dec 31, 2020 | 283 | 56 | 24.67% |
Dec 31, 2019 | 227 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
IMTX News
- 2 months ago - Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME - GlobeNewsWire
- 3 months ago - Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME - GlobeNewsWire
- 4 months ago - Immatics: A Promising TCR Pipeline - Seeking Alpha
- 4 months ago - Immatics Announces Pricing of $150 Million Public Offering - GlobeNewsWire
- 4 months ago - Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday? - Benzinga
- 4 months ago - Immatics Announces Proposed $150 Million Public Offering - GlobeNewsWire
- 4 months ago - Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial - GlobeNewsWire
- 4 months ago - Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 - GlobeNewsWire